Aurinia Pharmaceuticals ( (AUPH) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aurinia Pharmaceuticals’ stock took a hit after Leerink downgraded the company from Outperform to Market Perform. The downgrade was driven by concerns over the long-term sales potential of Lupkynis, despite its successful commercialization. Additionally, competitive challenges surrounding aritinercept have raised questions about its differentiation in the market.
More about Aurinia Pharmaceuticals
YTD Price Performance: 84.38%
Average Trading Volume: 1,786,209
Technical Sentiment Signal: Buy
Current Market Cap: $2.13B
For further insights into AUPH stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.